NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China.
Key Laboratory of AIDS Immunology of Liaoning Province, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China.
Chin Med J (Engl). 2021 Nov 10;134(23):2799-2809. doi: 10.1097/CM9.0000000000001842.
In the past 37 years, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) has undergone various major transmission routes in China, with the world most complex co-circulating HIV-1 subtypes, even the prevalence is still low. In response to the first epidemic outbreak of HIV in injecting drug users and the second one by illegal commercial blood collection, China issued the Anti-Drug Law and launched the Blood Donation Act and nationwide nucleic acid testing, which has avoided 98,232 to 211,200 estimated infections and almost ended the blood product-related infection. China has been providing free antiretroviral therapy (ART) since 2003, which covered >80% of the identified patients and achieved a viral suppression rate of 91%. To bend the curve of increasing the disease burden of HIV and finally end the epidemic, China should consider constraining HIV spread through sexual transmission, narrowing the gaps in identifying HIV cases, and the long-term effectiveness and safety of ART in the future.
在过去的 37 年中,人类免疫缺陷病毒/获得性免疫缺陷综合征(HIV/AIDS)在中国经历了各种主要的传播途径,存在世界上最复杂的 HIV-1 亚型共流行情况,尽管流行率仍然较低。针对首次由静脉注射吸毒者引起的 HIV 疫情和第二次由非法商业采供血引起的疫情,中国颁布了《禁毒法》,并出台了《献血法》和全国范围内的核酸检测,避免了 98232 至 211200 例估计的感染,几乎结束了与血液制品相关的感染。自 2003 年以来,中国一直在提供免费的抗逆转录病毒治疗(ART),覆盖了>80%的确诊患者,实现了 91%的病毒抑制率。为了减缓 HIV 导致疾病负担增加的曲线,最终结束疫情,中国应考虑通过性传播来限制 HIV 的传播,缩小 HIV 病例识别方面的差距,以及未来 ART 的长期有效性和安全性。
Chin Med J (Engl). 2021-11-10
Medicine (Baltimore). 1995-3
AIDS Educ Prev. 2004-6
Science. 2004-6-4
Infect Dis Clin North Am. 2000-12
Int J Health Serv. 1991
BMC Infect Dis. 2025-8-19
Patient Prefer Adherence. 2025-3-4